Transfer factor immunotherapy in Hodgkin's and non-Hodgkin's lymphoma

Summary Human dialyzable transfer factor was administered in a double-blind fashion to patients with Hodgkin's disease and non-Hodgkin's lymphoma. Two groups were examined; patients with active disease and patients in remission. Parameters of cellular and humoral immunity were studied. The effect of transfer factor on the clinical condition was not evaluated.Transfer factor tended to intensify the skin test reactions of patients in remission to several recall antigens, but had no effect on the other parameters or the other patient group.